A qualitative diagnostic test for the detection of targeted 74 DNA mutation hotspots in non-small cell lung cancer (NSCLC) using circulating cell-free DNA (cfDNA). This assay enables advanced molecular testing for oncology applications.
Manufactured by
Taipei City, Taiwan
About PlexBio PlexBio Co., Ltd., founded in 2010 and headquartered in Taiwan, is a leading developer and manufacturer of multiplex in vitro diagnostic (IVD) solutions tailored for precision medicine. At the core of PlexBio s innovation is the patented πCode® MicroDisc technology, enabling simultaneous detection of dozens to hundreds of genetic mutations or biomarkers in a single reaction. This forms the basis of the IntelliPlex® platform , supporting applications in oncology, infectious diseases, and immunoassays. To streamline laboratory workflows, PlexBio developed the IntelliPrep TRIO 240 —a fully automated sample preparation system that integrates nucleic acid extraction, quantification, normalization, and PCR assay setup. Supporting up to 24 samples per run, TRIO 240 reduces hands-on time and minimizes human error, while ensuring standardized sample prep for downstream applications such as qPCR, dPCR, NGS, or PlexBio's πCode-based detection. PlexBio is committed to improving diagnostic accuracy, reducing testing costs, and enhancing patient outcomes by delivering innovative, scalable, and cost-effective molecular testing solutions. With ISO 13485, GMP, CE-IVD, and FDA-listed products, PlexBio continues to expand globally through clinical collaborations, RUO/LDT applications, and distribution partnerships.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
ID SOLUTIONS SAS
France · 1 relevant product
Biopsense Oy
Finland · 4 relevant products
LifeOS Genomics Corporation
Taiwan · 3 relevant products
Nonacus
United Kingdom · 4 relevant products
Genes 2Me Private Ltd
India · 3 relevant products
YouSeq
United Kingdom · 2 relevant products
U-GEN BIOTECHNOLOGY INC.
China · 1 relevant product
Yaneng BIOscience (Shenzhen) Co.,Ltd.
China · 1 relevant product
BioChain (Beijing) Science & Technology. Inc.
China · 3 relevant products
Singlera GENOMICS (SHANGHAI) Ltd.
China · 7 relevant products
37 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →3 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 88 closest product alternatives
ID SOLUTIONS SAS · France
ADELIS is a cell-free DNA (cfDNA) diagnostic test for non-invasive prenatal testing and cancer screening. The test analyzes circulating DNA fragments in blood samples to detect chromosomal abnormalities and genetic variations with high sensitivity and specificity. ADELIS enables early disease detection and risk stratification in clinical and prenatal care settings.
Biopsense Oy · Finland
Cell-free DNA (cfDNA) liquid biopsy test for non-invasive cancer diagnosis and treatment monitoring. Analyzes circulating tumor DNA in blood to detect cancer-causing mutations and guide personalized oncology treatment decisions. Reduces need for invasive tissue sampling and enables frequent monitoring for treatment response assessment.
LifeOS Genomics Corporation · Taiwan
Assay system for detecting and quantitating cell-free DNA in liquid biopsy samples. Used in prenatal testing and cancer diagnostics with high sensitivity and multiplexing capabilities through the QLoci platform.
Nonacus · United Kingdom
Custom NGS panels for targeted resequencing using Cell3 Target technology to convert cell-free DNA (cfDNA), genomic DNA (gDNA), and formalin-fixed paraffin-embedded (FFPE) DNA into libraries for next-generation sequencing. The panels are validated for ctDNA, gDNA, and FFPE DNA samples for oncology applications including early cancer detection and cancer monitoring. They incorporate error suppression technology with unique molecular indexes (UMIs) and unique dual indexes (UDIs) to enable confident variant calling down to 0.1% VAF, with support for as little as 1 ng of genomic or cfDNA input and 10 ng of FFPE material.
Biopsense Oy · Finland
Blood-based diagnostic test for monitoring cancer treatment efficacy and detecting emerging drug resistance through analysis of circulating tumor DNA. Enables rapid treatment adjustment decisions based on genetic mutation detection in cfDNA.
LifeOS Genomics Corporation · Taiwan
QLoci-based assay panel for non-invasive prenatal testing that identifies and quantitates fetal cell-free DNA (cfDNA) fragments. Provides genetic screening with minimal sample requirements and high sensitivity.
Genes 2Me Private Ltd · India
Specialized NGS panel for lung cancer genomics and clinical diagnostics. Delivers targeted genetic profiling for oncology applications in pulmonary disease.
YouSeq · United Kingdom
An NGS-based panel for detection of inherited genetic mutations associated with hereditary cancer syndromes. Enables identification of cancer predisposition for risk stratification and preventive clinical decision-making.
U-GEN BIOTECHNOLOGY INC. · China
Proprietary circulating tumor DNA analysis platform offering high accuracy and sensitivity for early cancer detection. Provides precision diagnosis for personalized cancer management and monitoring.
Biopsense Oy · Finland
Blood test panel for detecting and characterizing genetic and epigenetic mutations in circulating tumor DNA. Helps determine cancer origin, measure tumor burden, and identify new mutations during targeted therapy treatment.
Yaneng BIOscience (Shenzhen) Co.,Ltd. · China
Comprehensive genetic screening kit for lung cancer biomarkers and mutations. Enables early detection and treatment planning for pulmonary malignancies.
BioChain (Beijing) Science & Technology. Inc. · China
Advanced early detection test for lung cancer screening utilizing molecular diagnostic technology. This in-development product represents the company's expansion into early detection for pulmonary malignancies. The test is designed for high-risk population screening and clinical intervention.
76 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products